» Articles » PMID: 11561058

Unveiling the Functions of Presynaptic Metabotropic Glutamate Receptors in the Central Nervous System

Overview
Specialty Pharmacology
Date 2001 Sep 19
PMID 11561058
Citations 246
Authors
Affiliations
Soon will be listed here.
Abstract

Metabotropic glutamate (mGlu) receptors, which include mGlu1-8 receptors, are a heterogeneous family of G-protein-coupled receptors which function to modulate brain excitability via presynaptic, postsynaptic and glial mechanisms. Certain members of this receptor family have been shown to function as presynaptic regulatory mechanisms to control release of neurotransmitters. In general, Gi-coupled mGlu receptor subtypes appear to negatively modulate excitatory (and possibly also inhibitory) neurotransmitter output when activated. Localization studies have shown that mGlu7 is restricted to the presynaptic grid at the site of vesicle fusion. These studies along with other evidence suggest that mGlu7 is the nerve terminal autoreceptor that regulates physiological release of glutamate. Other mGlu subtypes, in particular mGlu2, mGlu8, and possibly mGlu4, are also localized presynaptically, but at perisynaptic sites outside the active zone of neurotransmitter release. Gi-coupled mGlu receptors also may exist on presynaptic elements of neighboring gamma-aminobutyric acid (GABA) neurons where they play a role in heterosynaptic suppressions of GABA release. This suggests that these receptors may have evolved to monitor glutamate that has "spilled" out of the synapse. Thus, they may serve as the brain's evolutionary mechanism to prevent pathological changes in neuronal excitability and thus maintain homeostasis. Recent progress on the molecular and pharmacological aspects of these presynaptic mGlu receptors is unveiling their functions and the therapeutic directions of agents designed for these novel glutamate receptor targets.

Citing Articles

Triggered temptations: A new procedure to compare reward-seeking behaviour induced by discriminative and conditioned stimuli in rats.

LeCocq M, Najafipashaki S, Casale D, Laplante I, Samaha A Psychopharmacology (Berl). 2025; .

PMID: 39994055 DOI: 10.1007/s00213-025-06764-4.


The anti-dyskinetic effect of the clinic-ready mGluRpositive allosteric modulator AZD8529 in the 6-OHDA-lesioned rat.

Shaqfah J, Kang W, Gaudette F, Khalil M, Kwan C, Belliveau S Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39841218 DOI: 10.1007/s00210-024-03627-1.


Dysbindin-1 Mutation Alters Prefrontal Cortex Extracellular Glutamate and Dopamine In Vivo.

Szumlinski K, Datko M, Lominac K, Jentsch J Int J Mol Sci. 2024; 25(23).

PMID: 39684450 PMC: 11640900. DOI: 10.3390/ijms252312732.


LY354740, an agonist of glutamatergic metabotropic receptor mGlu increases the cytochrome P450 2D (CYP2D) activity in the frontal cortical area of rat brain.

Bromek E, Haduch A, Puklo R, Daniel W Pharmacol Rep. 2024; 76(6):1482-1488.

PMID: 39496920 PMC: 11582139. DOI: 10.1007/s43440-024-00675-5.


Metabotropic Glutamate Receptor 5: A Potential Target for Neuropathic Pain Treatment.

Manengu C, Zhu C, Zhang G, Tian M, Lan X, Tao L Curr Neuropharmacol. 2024; 23(3):276-294.

PMID: 39411936 PMC: 11808587. DOI: 10.2174/1570159X23666241011163035.